Login | New Member? Signup Free
ChangeDetect » News

Alnylam Receives Notice Of Allowance From United States Patent And Trademark Office For New Patents From The

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced recently that the United States Patent and Trademark Office has issued Notices of Allowance for three patent applications from the company’s exclusively held Tuschl II patent estate.

Tags: , , , , , , , , , , , , ,

With Key RNAi Patent In Hand, PBL Aims to Make Technology Widely Available

Having secured a fundamental RNAi-related US patent earlier this year, UK-based technology management firm Plant Bioscience Limited has begun the process of hammering out deals with organizations interested in licensing the intellectual property.

Tags: , , , , , ,

Alnylam receives U.S. patent allowance for LNP platform

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for patent application number 12/813,448, covering the company's proprietary second generation lipid nanoparticle platform, including the "MC3" lipid.

Tags: , , , , , , , , , , , , , , ,

Novartis, Alcon Join Alnylam in Opposing Silence Patent in Europe

Drug makers Novartis and Alcon have joined Alnylam Pharmaceuticals in opposing a European patent held by Silence Therapeutics covering a key RNAi molecule-design technology, according to documents on file with the European Patent Office. (1 day ago)

Tags: , , , , , , , ,